Organigram Expands Into Australia's Booming Medical Cannabis Market With New Vape And Pastille Products

Organigram Global Inc. ("Organigram" or the "Company") today announced the expansion of its international product portfolio, with the launch of Edison and BOXHOT medical cannabis vape and pastille products in Australia.

Australia has become one of the world's most dynamic medical cannabis markets, with increasing approvals for access and prescribers utilising a broader range of dosage forms1. While flower remains a core category, alternatives such as vapes and pastilles are gaining importance, driven by demand for consistent dosing, ease of administration, and discreet, ready-to-use formats. These trends position Organigram, recognized for its expertise in developing high‑quality, non‑flower cannabis product formats anchored in need-state specific formulations, to have a central role as the market evolves.